To request a free sample copy of this report, please complete the form below.
What people say about us!

"We have purchased recently a report from SkyQuest Technology, and we are happy to inform you that this report was so useful and practical for our team. Skyquest Team was very active and our queries were followed up completely.It was amazing. "

- Mr. Ali Zali, Commercial Director, ICIIC Iran.

logos logos logos logos logos
Analyst Support
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.



Mycoplasma Testing Market size was valued at USD 262.2 Million in 2021 and is poised to grow from USD 298.91 Million in 2022 to USD 852.66 Million by 2030, at a CAGR of 14% during the forecast period (2023-2030).

The nature of the global mycoplasma testing market is highly competitive owing to the presence of several established players and new entrants. The market players are focusing on developing advanced technologies and solutions, expanding their product portfolios, and establishing strategic partnerships and collaborations to strengthen their position in the market. The Mycoplasma testing market is expected to continue to grow and evolve, driven by technological advancements, increasing demand for biopharmaceuticals and cell-based therapies, and stringent regulatory requirements. The market players are likely to continue to invest in R&D and innovation to develop more efficient, accurate, and cost-effective testing solutions to meet the growing demand from customers. 'Merck KGaA (Germany)', 'Thermo Fisher Scientific Inc. (US)', 'Lonza Group Ltd. (Switzerland)', 'Sartorius AG (Germany)', 'PromoCell GmbH (Germany)', 'American Type Culture Collection (ATCC) (US)', 'Agilent Technologies, Inc. (US)', 'Bionique Testing Laboratories, Inc. (US)', 'Biological Industries Israel Beit Haemek Ltd. (Israel)', 'Charles River Laboratories International, Inc. (US)', 'Creative Bioarray (US)', 'InvivoGen (US)', 'Minerva Biolabs GmbH (Germany)', 'Biological Industries US, Inc. (US)', 'Norgen Biotek Corp. (Canada)', 'Novacyt Group (UK)', 'Mycoplasma Experience (France)', 'Genscript Biotech Corporation (China)', 'GeneCopoeia, Inc. (US)', 'Jena Bioscience GmbH (Germany)'

The growing demand for biopharmaceuticals and cell-based therapies is driving the Mycoplasma testing market. These products and therapies require high-quality cells that are free from Mycoplasma contamination to ensure their safety and efficacy.

Development of advanced testing technologies and platforms: The Mycoplasma testing market is witnessing the development of advanced technologies and platforms, such as PCR-based assays, nucleic acid sequencing, and flow cytometry, that offer higher sensitivity, specificity, and speed compared to traditional culture-based methods.

In 2022, North America dominated the market and accounted for a revenue share of 40.0%. Due to the well-established healthcare sector in this business and the increased prevalence of respiratory illnesses, market share growth is predicted. The existence of multinational pharmaceutical and biotech corporations in the area, as well as increased investment in R&D operations, are other factors contributing to the growth of this region.

Feedback From Our Clients

Global Mycoplasma Testing Market

Product ID: SQMIG35I2167